Zoryve (roflumilast topical) is not a Janus kinase (JAK) inhibitor. It is a phosphodiesterase 4 (PDE4) inhibitor [1].
How does Zoryve work?
Zoryve targets PDE4, an enzyme involved in inflammation. By inhibiting PDE4, roflumilast topical reduces the release of pro-inflammatory mediators in the skin, thereby decreasing inflammation associated with dermatological conditions [1].
What is Zoryve used for?
Zoryve is approved for the topical treatment of plaque psoriasis, including the intertriginous areas, in patients 12 years of age and older [1].
How does Zoryve compare to JAK inhibitors for psoriasis?
While both Zoryve and JAK inhibitors are used to treat inflammatory conditions like psoriasis, they work through different mechanisms. JAK inhibitors block signaling pathways mediated by Janus kinases, which are critical for the immune response. Zoryve, as a PDE4 inhibitor, acts on a different inflammatory pathway [1]. The choice between these treatments often depends on the specific patient profile, disease severity, and potential side effect considerations.
What is the regulatory status of Zoryve?
Zoryve received FDA approval for its indicated use in plaque psoriasis [1].
What are the potential side effects of Zoryve?
The most common side reaction reported in clinical trials was diarrhea [1].
When does Zoryve's patent expire?
Information regarding the specific patent expiry dates for Zoryve can be found on specialized drug patent databases. Websites like DrugPatentWatch.com provide detailed patent information for pharmaceutical products [2].